June 2009

TABLE OF CONTENTS

The Superhero Complex
Derek G. Hennecke, MBA, continues with part 3 of this 6-part series covering unique strategies for building lasting competitive advantages. 

Mimetic Drug Delivery Systems for Release With Specific Molecular Triggers
Lisa Brannon-Peppas, PhD, reviews the unique use of molecular imprinting Affinimer technology, which enables the creation of entirely synthetic smart polymers that are tailored to have various recognition properties and functions.

Subcutaneous Delivery of Small Molecule Formulations: An Insight Into Biopharmaceutics & Formulation Strategies

Viral Kansara, PhD; Amitava Mitra, PhD; and Yunhui Wu, PhD, provide an insight into biopharmaceutical and formulation aspects of systemic delivery of small molecules upon SC administrations, the factors that govern SC absorption, and research and technologies focused on utilizing or modifying SC absorption mechanisms.

 

Antibiotic Drug Delivery for Post-Surgical Infections

Mayur Bafna and Ganga Srinivasan, PhD, review treatment of post-surgical infections using biodegradable implants of antibiotics that will be able to overcome a number of concerns.

 

Thermoresponsive Drug Delivery Systems: Fiction or Reality?

Akm Khairuzzaman, PhD, explores an interesting smart drug delivery system, in which the drug molecule is physically attached to or entrapped in a polymer that is capable of conformational or phase changes under different regimes of temperature, as a potential candidate for targeted delivery, especially for anti-cancer drugs.

 

SPI Pharma: Formulating Success With Patient-Friendly Dosages

Drug Delivery Executive: Sarath Chandar, Vice President of Excipients and Drug Delivery Systems discusses his company’s path forward in patient-friendly formats.

 

Changing Tides in Formulation Outsourcing

Contributor Cindy H. Dubin recently asked some formulation development contractors how they are setting themselves apart from their competition during these trying times and how their current and potential clients can benefit.

 

Embryonic Stem Cells: Moving Ahead in 2009

Frost & Sullivan Analyst Kathryn Symank says that despite their potential, embryonic stem cells are surrounded by controversy, which has resulted in major roadblocks. However, research is progressing, thanks to both private and state funding.

 

 

DEPARTMENTS

 

Market News & Trends

 

Attorney Review      

The Curious Case of Thrifty Patent Procurement

 

Technology Showcase

 

External Delivery

Don’t Be the Bad News Bears

COVER

FEATURES